Casuistry
Experience with sunitinib in hormone-resistant metastatic prostate cancer that is unresponsive to docetaxel
Experiencia con sunitinib en cáncer de próstata metastásico hormonorresistente sin respuesta a docetaxel
J.M. Gasenta,
, E. Grandeb, J. Casinelloc, M. Provenciod, J.B. Laforgae, V. Alberolaf
Corresponding author
a Servicio de Oncología Médica, Hospital de Denia, Alicante, Spain
b Servicio de Oncología Médica, Hospital Universitario Ramón y Cajal, Madrid, Spain
c Servicio de Oncología Médica, Hospital Universitario de Guadalajara, Guadalajara, Spain
d Servicio de Oncología Médica, Hospital Universitario Puerta de Hierro, Madrid, Spain
e Servicio de Anatomia Patológica, Hospital de Denia, Alicante, Spain
f Servicio de Oncología Médica, Hospital Arnau de Vilanova, Valencia, Spain
Read
535
Timeswas read the article
487
Total PDF
48
Total HTML
| Year/Month | Html | Total | |
|---|---|---|---|
| 2025 12 | 0 | 4 | 4 |
| 2025 11 | 0 | 10 | 10 |
| 2025 10 | 0 | 8 | 8 |
| 2025 9 | 0 | 12 | 12 |
| 2025 8 | 0 | 17 | 17 |
| 2025 7 | 0 | 5 | 5 |
| 2025 6 | 0 | 2 | 2 |
| 2025 5 | 0 | 4 | 4 |
| 2025 4 | 0 | 2 | 2 |
| 2025 3 | 0 | 2 | 2 |
| 2025 2 | 0 | 4 | 4 |
| 2025 1 | 0 | 3 | 3 |
| 2024 12 | 0 | 5 | 5 |
| 2024 11 | 0 | 2 | 2 |
| 2024 10 | 0 | 10 | 10 |
| 2024 9 | 0 | 3 | 3 |
| 2024 8 | 0 | 4 | 4 |
| 2024 7 | 0 | 4 | 4 |
| 2024 6 | 0 | 1 | 1 |
| 2024 5 | 0 | 4 | 4 |
| 2024 4 | 0 | 7 | 7 |
| 2024 3 | 0 | 5 | 5 |
| 2024 2 | 0 | 4 | 4 |
| 2024 1 | 0 | 3 | 3 |
| 2023 12 | 0 | 6 | 6 |
| 2023 11 | 0 | 14 | 14 |
| 2023 10 | 0 | 12 | 12 |
| 2023 9 | 0 | 3 | 3 |
| 2023 8 | 0 | 2 | 2 |
| 2023 7 | 0 | 32 | 32 |
| 2023 6 | 0 | 4 | 4 |
| 2023 5 | 0 | 7 | 7 |
| 2023 4 | 0 | 8 | 8 |
| 2023 3 | 1 | 3 | 4 |
| 2023 2 | 0 | 6 | 6 |
| 2023 1 | 0 | 3 | 3 |
| 2022 12 | 0 | 4 | 4 |
| 2022 11 | 0 | 11 | 11 |
| 2022 10 | 0 | 9 | 9 |
| 2022 9 | 0 | 13 | 13 |
| 2022 8 | 0 | 9 | 9 |
| 2022 7 | 0 | 1 | 1 |
| 2022 5 | 0 | 2 | 2 |
| 2022 4 | 0 | 5 | 5 |
| 2022 3 | 0 | 6 | 6 |
| 2022 2 | 0 | 3 | 3 |
| 2022 1 | 0 | 1 | 1 |
| 2021 12 | 0 | 2 | 2 |
| 2021 11 | 0 | 2 | 2 |
| 2021 9 | 0 | 2 | 2 |
| 2021 7 | 0 | 3 | 3 |
| 2021 6 | 0 | 2 | 2 |
| 2021 4 | 0 | 8 | 8 |
| 2021 3 | 0 | 1 | 1 |
| 2021 2 | 0 | 1 | 1 |
| 2021 1 | 0 | 3 | 3 |
| 2020 12 | 0 | 2 | 2 |
| 2020 10 | 0 | 3 | 3 |
| 2020 9 | 0 | 1 | 1 |
| 2020 8 | 0 | 3 | 3 |
| 2020 7 | 0 | 2 | 2 |
| 2020 6 | 0 | 5 | 5 |
| 2020 5 | 0 | 1 | 1 |
| 2020 4 | 0 | 2 | 2 |
| 2020 3 | 0 | 2 | 2 |
| 2020 2 | 0 | 3 | 3 |
| 2020 1 | 0 | 8 | 8 |
| 2019 12 | 0 | 9 | 9 |
| 2019 11 | 0 | 2 | 2 |
| 2019 10 | 0 | 9 | 9 |
| 2019 9 | 0 | 3 | 3 |
| 2019 8 | 0 | 5 | 5 |
| 2019 7 | 0 | 3 | 3 |
| 2019 6 | 0 | 8 | 8 |
| 2019 5 | 0 | 50 | 50 |
| 2019 4 | 0 | 2 | 2 |
| 2019 3 | 0 | 1 | 1 |
| 2019 1 | 0 | 1 | 1 |
| 2018 12 | 0 | 7 | 7 |
| 2018 11 | 0 | 1 | 1 |
| 2018 10 | 0 | 2 | 2 |
| 2018 9 | 0 | 2 | 2 |
| 2018 7 | 0 | 1 | 1 |
| 2018 2 | 3 | 1 | 4 |
| 2017 12 | 0 | 1 | 1 |
| 2017 11 | 0 | 1 | 1 |
| 2017 10 | 2 | 0 | 2 |
| 2017 9 | 0 | 8 | 8 |
| 2017 8 | 1 | 3 | 4 |
| 2017 7 | 3 | 2 | 5 |
| 2017 6 | 0 | 2 | 2 |
| 2017 5 | 3 | 2 | 5 |
| 2017 4 | 6 | 1 | 7 |
| 2017 3 | 7 | 8 | 15 |
| 2017 2 | 0 | 5 | 5 |
| 2016 12 | 3 | 0 | 3 |
| 2016 11 | 3 | 0 | 3 |
| 2016 10 | 9 | 2 | 11 |
| 2016 9 | 1 | 0 | 1 |
| 2016 8 | 6 | 0 | 6 |
Show all
